Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: An updated meta-analysis of randomized placebo-controlled trials

This publication has 14 references indexed in Scilit:

• NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials
  Journal of Psychiatric Research, 2013
• Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
  The Lancet, 2013
• Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study
  Psychiatry Investigation, 2012
• Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
  JAMA, 2009
• Improvement of Negative and Positive Symptoms in Treatment-Refractory Schizophrenia
  The Journal of Clinical Psychiatry, 2009
• Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
  The Lancet, 2009
• Double-Blind, Placebo-Controlled Investigation of Amantadine for Weight Loss in Subjects Who Gained Weight With Olanzapine
  American Journal of Psychiatry, 2005
• Amantadine for weight gain associated with olanzapine treatment
  European Neuropsychopharmacology, 2005
• Discrepancies between Meta-Analyses and Subsequent Large Randomized, Controlled Trials
  New England Journal of Medicine, 1997
• A Controlled Trial of Amantadine Hydrochloride and Neuroleptics in the Treatment of Tardive Dyskinesia
  Journal of Clinical Psychopharmacology, 1997